Clinical utility of technetium-99m methoxisobutylisonitrile imaging in differentiated thyroid carcinoma: comparison with thallium-201 and iodine-131 Na scintigraphy, and serum thyroglobulin quantitation
- PMID: 8575487
- DOI: 10.1007/BF00801623
Clinical utility of technetium-99m methoxisobutylisonitrile imaging in differentiated thyroid carcinoma: comparison with thallium-201 and iodine-131 Na scintigraphy, and serum thyroglobulin quantitation
Abstract
Recently, technetium-99m methoxyisobutylisonitrile (99mTc-MIBI) has been used to image thyroid carcinoma. A prospective study was performed to compare the efficacy of 99mTc-MIBI to thallium-201 (201Tl) scintigraphy in patients with differentiated thyroid carcinoma. The clinical utility of all radionuclide imaging modalities, i.e., 99mTc-MIBI, 201Tl, and iodine-131 Na (131I-Na), as well as serum thyroglobulin estimation, was evaluated. Thirty-four post-thyroidectomy patients (age range: 26-76 years) underwent 45 studies. Histopathologies studied included fourteen papillary, eight papillary-follicular, ten follicular, one Hürthle cell, and one medullary carcinoma of the thyroid. Following optimal stimulation of endogenous thyroid stimulating hormone (i.e, TSH 50 mU/ml), the patients underwent 201Tl and 99mTc-MIBI scintigraphy. Concomitant 131I-Na scintigraphy was performed and serum thyroglobulin levels were measured. Sixteen scan sets were performed prior to 131I-Na ablation therapy. Twenty-nine scan sets were performed following 131I-Na ablation therapy. The presence or absence of thyroid cancer was established by clinical, biochemical, radiologic, and/or biopsy findings. There was no significant difference in sensitivity and specificity of 201Tl scintigraphy versus 99mTc-MIBI scintigraphy in pre- and postablation studies. 131I-Na scintigraphy with determination of thyroglobulin level was sufficient in preablation studies. Among postablation patients, the addition of 99mTc-MIBI or 201Tl offered a higher diagnostic yield. Between the 201Tl and 99mTc-MIBI studies, there was a concordance of 69% in preablation and 97% among postablation patients (P=0.027). It is concluded that 99mTc-MIBI is a suitable alternative to 201Tl scintigraphy in thyroid carcinoma, especially following thyroidectomy and 131I-Na therapy. 131I-Na scintigraphy with serum thyroglobulin is adequate in both pre- and postablation patients. Among the post-131I-Na ablation patients, 99mTc-MIBI or 201Tl is extremely valuable for tumor localization, especially when the 131I-Na whole-body scan is negative. The combination of 99mTc-MIBI or 201Tl scintigraphy with 131I-Na and serum thyroglobulin offers the highest diagnostic yield.
Similar articles
-
[Evaluation of technetium-99m-MIBI scintigraphy in metastatic differentiated thyroid cancer--comparison study with 131I and 201Tl].Kaku Igaku. 2000 Mar;37(2):89-98. Kaku Igaku. 2000. PMID: 10783567 Clinical Trial. Japanese.
-
The role of technetium-99m methoxyisobutylisonitrile scintigraphy in the planning of therapy and follow-up of patients with differentiated thyroid carcinoma after surgery.Eur J Nucl Med. 2000 Apr;27(4):431-40. doi: 10.1007/s002590050527. Eur J Nucl Med. 2000. PMID: 10805117
-
Comparison of 99mTc-methoxyisobutyl isonitrile and 201Tl scintigraphy for detection of residual thyroid cancer after 131I ablative therapy.J Nucl Med. 1999 Sep;40(9):1434-40. J Nucl Med. 1999. PMID: 10492361
-
Isotope imaging for metastatic thyroid cancer.Endocrinol Metab Clin North Am. 2001 Jun;30(2):469-92. doi: 10.1016/s0889-8529(05)70195-x. Endocrinol Metab Clin North Am. 2001. PMID: 11444171 Review.
-
[Diagnostic modalities in patients affected by differentiated thyroid carcinoma with high thyroglobulin levels and total body Iodium-131 negative: PET/CT use after recTSH].Minerva Endocrinol. 2004 Dec;29(4):151-60. Minerva Endocrinol. 2004. PMID: 15765025 Review. Italian.
Cited by
-
Recombinant TSH-stimulated, radioguided differentiated thyroid carcinoma surgery.Clin Med Res. 2003 Jan;1(1):53-6. doi: 10.3121/cmr.1.1.53. Clin Med Res. 2003. PMID: 15931286 Free PMC article.
-
99mTc-MIBI imaging in thyroid nodules: is it useful?Endocrine. 2014 May;46(1):1-2. doi: 10.1007/s12020-013-0051-7. Epub 2014 Feb 28. Endocrine. 2014. PMID: 24577805 No abstract available.
-
Use of 99mTc-sestamibi SPECT/CT when conventional imaging studies are negative for localizing suspected recurrence in differentiated thyroid cancer: a method and a lesson for clinical management.Endocrine. 2018 Oct;62(1):57-63. doi: 10.1007/s12020-018-1636-y. Epub 2018 May 24. Endocrine. 2018. PMID: 29797211
-
Parathyroid Imaging: Past, Present, and Future.Front Endocrinol (Lausanne). 2022 Feb 25;12:760419. doi: 10.3389/fendo.2021.760419. eCollection 2021. Front Endocrinol (Lausanne). 2022. PMID: 35283807 Free PMC article. Review.
-
Comparison of whole-body 18F-FDG PET, 99mTc-MIBI SPET, and post-therapeutic 131I-Na scintigraphy in the detection of metastatic thyroid cancer.Eur J Nucl Med Mol Imaging. 2004 Apr;31(4):491-8. doi: 10.1007/s00259-003-1403-y. Epub 2003 Dec 10. Eur J Nucl Med Mol Imaging. 2004. PMID: 14666387 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials